Eisai and Biogen are now working on the next steps after the TGA confirmed its non-approval of lecanemab for the treatment of mild cognitive impairment due to Alzheimer’s disease and early Alzheimer’s disease.
Eisai and Biogen working on next steps after TGA confirms non-approval of Alzheimer’s therapy
March 4, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
Mark Butler: Patients waiting too long and 'as the Health Minister, of course, I am sorry for that'
March 24, 2025 - - Latest News -
Call for safety net change with half a million Australians missing out on cheaper medicines
March 24, 2025 - - Latest News -
Nanotechnology could improve odds in treating aggressive breast cancers
March 24, 2025 - - Latest News -
Industry pushes back on conspiracy theories, highlighting the Government's own comments
March 22, 2025 - - Latest News -
Medicines Australia announces appointment of new board chair
March 20, 2025 - - Latest News -
The 'Week in Review Dispatched' Podcast - 21 March
March 20, 2025 - - Podcast -
New NZ approval clears the way for expanded access to cystic fibrosis therapy
March 20, 2025 - - Latest News